Acorda Therapeutics (ACOR -1%) is issued a patent for Amprya entitled "Methods of Using...

|About: Acorda Therapeutics, Inc. (ACOR)|By:, SA News Editor

Acorda Therapeutics (ACOR -1%) is issued a patent for Amprya entitled "Methods of Using Sustained Release Aminopyridine Compositions." This patent covers a range of dosage strengths, and is separate from 2 method of use patents issued in 2011 and 2013 that are set to expire in 2027 and 2026, respectively. The drug is approved in the United States as a treatment to improve walking in patients with multiple sclerosis.